NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis $2.04 0.00 (0.00%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$2.04 0.00 (-0.25%) As of 08/7/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Pulmonx Stock (NASDAQ:LUNG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pulmonx alerts:Sign Up Key Stats Today's Range$2.01▼$2.1050-Day Range$1.17▼$2.1252-Week Range$1.13▼$2.89Volume446,569 shsAverage Volume724,802 shsMarket Capitalization$87.62 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingModerate Buy Company Overview Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes. The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe. Pulmonx supports its commercial portfolio with comprehensive physician training programs, ongoing clinical research collaborations, and robust post-market surveillance initiatives. These efforts help validate long-term safety and efficacy, while also guiding future enhancements and potential label expansions for its technologies. Headquartered in Redwood City, California, Pulmonx maintains an international presence through offices and distribution partners in Europe. Under the leadership of President and Chief Executive Officer Antonio Pizarro, the company continues to advance its mission of improving the quality of life for patients with obstructive lung diseases. Pulmonx remains committed to innovation in minimally invasive therapies and to building strategic relationships with physicians and healthcare institutions worldwide.AI Generated. May Contain Errors. Read More Pulmonx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreLUNG MarketRank™: Pulmonx scored higher than 56% of companies evaluated by MarketBeat, and ranked 408th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPulmonx has a consensus price target of $7.67, representing about 275.8% upside from its current price of $2.04.Amount of Analyst CoveragePulmonx has only been the subject of 1 research reports in the past 90 days.Read more about Pulmonx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.70% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 4.64.Change versus previous monthShort interest in Pulmonx has recently decreased by 8.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentPulmonx has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pulmonx this week, compared to 2 articles on an average week.Search Interest3 people have searched for LUNG on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have not sold or bought any company stock.Percentage Held by Insiders7.50% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUNG Stock News HeadlinesPulmonx (LUNG) Q2 2026 Earnings Call TranscriptAugust 8 at 1:08 AM | finance.yahoo.comPulmonx reiterates $90M-$92M 2026 revenue outlook while targeting ~76% gross marginJuly 30, 2026 | seekingalpha.comWhy Trump really wants GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar. | Porter & Company (Ad)Pulmonx Corporation (LUNG) Q2 2026 Earnings Call TranscriptJuly 30, 2026 | seekingalpha.comPulmonx Reports Second Quarter 2026 Financial ResultsJuly 29, 2026 | globenewswire.comPulmonx to Present at the Canaccord Genuity 46th Annual Growth ConferenceJuly 28, 2026 | globenewswire.comPulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026July 15, 2026 | globenewswire.comPulmonx Stock Dividends | NASDAQ:LUNG | BenzingaJune 27, 2026 | benzinga.comSee More Headlines LUNG Stock Analysis - Frequently Asked Questions How have LUNG shares performed this year? Pulmonx's stock was trading at $2.21 at the beginning of the year. Since then, LUNG shares have decreased by 7.7% and is now trading at $2.04. How were Pulmonx's earnings last quarter? Pulmonx Corporation (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday, July, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. The company earned $22.76 million during the quarter, compared to analyst estimates of $22.39 million. Pulmonx had a negative trailing twelve-month return on equity of 96.66% and a negative net margin of 55.03%. Read the conference call transcript. When did Pulmonx IPO? Pulmonx (LUNG) raised $175 million in an initial public offering on Thursday, October 1st 2020. The company issued 10,000,000 shares at $17.00-$18.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's top institutional investors include BlackRock Inc. (2.05%), Deutsche Bank AG (0.94%), GSA Capital Partners LLP (0.32%) and Redhawk Wealth Advisors Inc. (0.24%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, Srikanth Radhakrishnan, Daniel P Florin, Richard Ferrari and John Mckune. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pulmonx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings7/29/2026Today8/10/2026Canaccord Genuity's 46th Annual Growth Conference8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 7 days, LUNG's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:LUNG CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees250Year Founded1998Price Target and Rating Average Price Target for Pulmonx$7.67 High Price Target$14.00 Low Price Target$4.00 Potential Upside/Downside+275.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54 million Net Margins-55.03% Pretax Margin-54.35% Return on Equity-96.66% Return on Assets-38.32% Debt Debt-to-Equity Ratio0.95 Current Ratio4.32 Quick Ratio3.52 Sales & Book Value Annual Sales$90.50 million Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.56Miscellaneous Outstanding Shares42,950,000Free Float39,727,000Market Cap$87.62 million OptionableOptionable Beta0.28 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:LUNG) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredI’ll Keep This Short… (Huge AI Opportunity)Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...Traders Agency | SponsoredAI Bubble Could Finally Be Done - Wall St's WarningWall Street analysts are warning that the AI-driven market rally may be nearing its limits, with some cautioni...TradeSmith | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
